This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
A missed dose in a weekly schedule is not a trough to chase. With a week-long half-life you are perturbing a slowly moving average, and the labelling for licensed products in this class says take it if the next dose is far enough away and skip it otherwise.
Helpful, and easy to find again, which is half of what a good reply is.
Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a good one.
Not the answer, but possibly the question that gets there.
The arithmetic in post #34 is right; the assumption feeding it is the part to check.
Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
The interesting part of this is the exception, and I do not understand the exception.
The version of lowest dose that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
Post #37 describes the usual case. This is about the unusual one.
Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.
It is a small point and it changes the answer, which is an awkward combination.
Adding the measurement that post #37 says would settle it.
My understanding of lowest dose is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.
The evidence for this is thinner than the way I have phrased it suggests.
Micro-titration: the concept of increments smaller than the labelled steps. It has no evidence base from trials but is described by some people. The downside is that very small increments are hard to measure accurately with a syringe.
It is the sort of thing that seems obvious in retrospect and was not at the time.
The arithmetic in post #42 is right; the assumption feeding it is the part to check.
If you are stepping up mainly because the schedule says so rather than because the current dose has stopped doing what you wanted, that is worth noticing before rather than afterwards.
Answering the question post #40 raises rather than the one it answers.
Nothing here is medical advice, and a titration question is one of the few where a prescriber can genuinely answer in a minute what a thread will take a week to circle.
The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.
Worth one more sentence than it usually gets.
Everything in post #44 holds. The case it does not cover is the one I have.
Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose. Escalating before steady state means escalating on incomplete information about the dose you are on.
On balance I think that is right, and I would not bet much on it.
Confirming post #47 from a second method, which matters more than confirming it from a second person.
Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.
I had written a reply contradicting post #48 and deleted it. Here is what survived.
Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.
Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose. The trials escalated to a target and then held that. What happens if you stay at an intermediate dose for years is not formally studied and extrapolation is the best available reasoning.
Not the whole picture, but the part of it I can speak to.
The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The reasoning is pharmacological — e.g., "I will split the difference between steps" — but it is reasoning from theory, not from evidence.
Adding the measurement that post #51 says would settle it.
Practical experience of lowest dose, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.
I am reporting what happened, not recommending it.
How the published trials escalated: they used specific step sizes and intervals. The STEP programme used a particular cadence; the SURPASS and SURMOUNT programmes used slightly different ones. Reading them side by side shows the variation is real but small.
The arithmetic in post #55 is right; the assumption feeding it is the part to check.
When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a reasonable response. If the side effect is not dose-dependent (e.g., hypoglycemia with insulin), dose reduction does not address the issue.
Someone should write this up properly, and it should probably not be me.
I read post #55 twice before replying, because I had assumed the opposite.
Holding at a dose that is working is a legitimate position and it is not what the trial protocols did. The protocols escalated to a target because they were measuring the target dose, not finding each person's minimum.
Post #59 answers the question as asked. The question underneath it is different.
Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.